PMID- 17408395
OWN - NLM
STAT- MEDLINE
DCOM- 20070906
LR  - 20131121
IS  - 0007-0963 (Print)
IS  - 0007-0963 (Linking)
VI  - 156
IP  - 6
DP  - 2007 Jun
TI  - Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to 
      standard therapy.
PG  - 1321-7
AB  - BACKGROUND: Approximately 75-95% of patients with cutaneous lupus erythematosus 
      respond to antimalarial therapy and/or topical glucocorticosteroids. 
      Immunosuppressive agents are usually considered a second-line approach in 
      patients with resistant disease. OBJECTIVES: This was a prospective, 
      nonrandomized, open pilot study to evaluate the efficacy of mycophenolate sodium 
      monotherapy in patients with recalcitrant subacute cutaneous lupus erythematosus 
      (SCLE). METHODS: Monotherapy with oral enteric-coated mycophenolate sodium 1440 
      mg daily was given for a total of 3 months. Treatment outcome was evaluated by 
      means of a validated clinical score for cutaneous lupus erythematosus, the 
      Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), as well as 
      20-MHz ultrasound measurements and colorimetry. Safety assessment included the 
      monitoring of adverse effects and clinical laboratory parameters. RESULTS: Ten 
      patients with active SCLE resistant to at least one standard therapy were 
      included in the trial. Mycophenolate sodium led to a remarkable improvement of 
      skin lesions, resulting in a significant decrease of the mean +/- SD CLASI from 
      10.8 +/- 6.0 at the beginning to 2.9 +/- 2.6 at the end of therapy. Clinical 
      improvement was confirmed by ultrasonographic assessments and colorimetry. No 
      serious side-effects were noted. CONCLUSIONS: Mycophenolate sodium is beneficial 
      and safe in the treatment of patients with SCLE that failed standard therapy. 
      However, these preliminary data must be confirmed by randomized controlled trials 
      including a larger sample size.
FAU - Kreuter, A
AU  - Kreuter A
AD  - Connective Tissue Disease Research Unit, Department of Dermatology and 
      Allergology, Ruhr University Bochum, Bochum, Germany. a.kreuter@derma.de
FAU - Tomi, N S
AU  - Tomi NS
FAU - Weiner, S M
AU  - Weiner SM
FAU - Huger, M
AU  - Huger M
FAU - Altmeyer, P
AU  - Altmeyer P
FAU - Gambichler, T
AU  - Gambichler T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070404
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Immunosuppressive Agents)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Adult
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Lupus Erythematosus, Cutaneous/complications/*drug therapy/immunology
MH  - Male
MH  - Middle Aged
MH  - Mycophenolic Acid/*administration & dosage
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2007/04/06 09:00
MHDA- 2007/09/07 09:00
CRDT- 2007/04/06 09:00
PHST- 2007/04/06 09:00 [pubmed]
PHST- 2007/09/07 09:00 [medline]
PHST- 2007/04/06 09:00 [entrez]
AID - BJD7826 [pii]
AID - 10.1111/j.1365-2133.2007.07826.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2007 Jun;156(6):1321-7. doi: 10.1111/j.1365-2133.2007.07826.x. 
      Epub 2007 Apr 4.